Peroxisome proliferator-activated receptor γ:: Implications for cardiovascular disease

被引:113
作者
Hsueh, WA [1 ]
Bruemmer, D [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA
关键词
atherosclerosis; diabetes mellitus; peroxisome proliferator-activated receptor; angiotensin; inflammation;
D O I
10.1161/01.HYP.0000113626.76571.5b
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Peroxisome proliferator-activated receptor gamma(PPARgamma) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. PPARgamma is expressed by macrophages, endothelial cells, and vascular smooth muscle cells. It regulates gene expression of key proteins involved in lipid metabolism, vascular inflammation, and proliferation contributing to atherogenesis and postangioplasty restenosis. The discovery of synthetic ligands for PPARgamma has led to significant enhancement of our understanding of the mechanism of their ligand-dependent activation and subsequent biological effects, particularly with respect to the role of PPARgamma in vascular pathophysiology. The thiazolidinedione PPARgamma agonists not only improve insulin resistance in patients with type II diabetes but also exert a broad spectrum of antiatherogenic effects in vitro and in animal models of atherosclerosis. In this review, we summarize the important role of PPARgamma as a molecular target for thiazolidinediones and its implications for the control of vascular inflammation and proliferation for the cardiovascular system.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 137 条
[1]   Adipose tissue as an endocrine organ [J].
Ahima, RS ;
Flier, JS .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (08) :327-332
[2]   Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management [J].
Beckman, JA ;
Creager, MA ;
Libby, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19) :2570-2581
[3]   The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J].
Berg, AH ;
Combs, TP ;
Du, XL ;
Brownlee, M ;
Scherer, PE .
NATURE MEDICINE, 2001, 7 (08) :947-953
[4]   C-reactive protein and other inflammatory risk markers in acute coronary syndromes [J].
Blake, GJ ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) :37S-42S
[5]   The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease [J].
Bodzioch, M ;
Orsó, E ;
Klucken, T ;
Langmann, T ;
Böttcher, L ;
Diederich, W ;
Drobnik, W ;
Barlage, S ;
Büchler, C ;
Porsch-Özcürümez, M ;
Kaminski, WE ;
Hahmann, HW ;
Oette, K ;
Rothe, G ;
Aslanidis, C ;
Lackner, KJ ;
Schmitz, G .
NATURE GENETICS, 1999, 22 (04) :347-351
[6]   Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J].
Boring, L ;
Gosling, J ;
Cleary, M ;
Charo, IF .
NATURE, 1998, 394 (6696) :894-897
[7]   Peroxisome proliferator-activated receptor γ inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells [J].
Bruemmer, D ;
Yin, F ;
Liu, J ;
Berger, JP ;
Kiyono, T ;
Chen, J ;
Fleck, E ;
Van Herle, AJ ;
Forman, BM ;
Law, RE .
MOLECULAR ENDOCRINOLOGY, 2003, 17 (06) :1005-1018
[8]   Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice [J].
Bruemmer, D ;
Collins, AR ;
Noh, G ;
Wang, W ;
Territo, M ;
Arias-Magallona, S ;
Fishbein, MC ;
Blaschke, F ;
Kintscher, U ;
Graf, K ;
Law, RE ;
Hsueh, WA .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (09) :1318-1331
[9]   BLOOD-PRESSURE-LOWERING BY PIOGLITAZONE - EVIDENCE FOR A DIRECT VASCULAR EFFECT [J].
BUCHANAN, TA ;
MEEHAN, WP ;
JENG, YY ;
YANG, D ;
CHAN, TM ;
NADLER, JL ;
SCOTT, S ;
RUDE, RK ;
HSUEH, WA .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :354-360
[10]   The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trial [J].
Caballero, AE ;
Saouaf, R ;
Lim, SC ;
Hamdy, O ;
Abou-Elenin, K ;
O'Connor, C ;
LoGerfo, FW ;
Horton, ES ;
Veves, A .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (02) :173-180